



Kala Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call

July 30, 2019

WALTHAM, Mass.--(BUSINESS WIRE)--Jul. 30, 2019-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report second quarter 2019 financial results on Tuesday, August 6, 2019. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 2677066. To access a live webcast and subsequent archived recording of the presentation, please visit "Events" in the "Investors" section of the Kala website at <http://kalarx.com/>.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in INVELTYS® which received FDA approval in August 2018 for the treatment of inflammation and pain following ocular surgery, and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease, for which a target action date under the Prescription Drug User Fee Act (PDUFA) has been set by the United States Food and Drug Administration (FDA) for August 15, 2019.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190730005810/en/>

Source: Kala Pharmaceuticals, Inc.

Investor:

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

Media:

Kari Watson
kwatson@macbiocom.com
781-235-3060